US Trastuzumab Competition Heats Up

Mylan And Biocon’s Ogivri Biosimilar Leads New Wave Of Herceptin Rivals

 
• By David Wallace
Horse racing
Mylan and Biocon follow Amgen into the biosimilar trastuzumab market, with other firms close behind • Source: Shutterstock

More from Biosimilars

More from Products